Generic Industry Wants US FDA To Consider Allowing Foreign Reference Products For ANDAs
Executive Summary
If agency adopts policy, it might obviate the need for the CREATES Act. Biosimilars already enjoy a degree flexibility of on the source of reference material that generic sponsors want extended to the less complicated small molecule drugs.